JBCHEPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.0
| Stock Code | JBCHEPHARM | Market Cap | 33,786 Cr. | Current Price | 2,101 ₹ | High / Low | 2,195 ₹ |
| Stock P/E | 46.4 | Book Value | 238 ₹ | Dividend Yield | 0.74 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 2,011 ₹ | DMA 200 | 1,877 ₹ |
| Chg in FII Hold | 1.45 % | Chg in DII Hold | -1.97 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 62.6 | MACD | 12.4 | Volume | 3,84,667 | Avg Vol 1Wk | 2,50,088 |
| Low price | 1,495 ₹ | High price | 2,195 ₹ | PEG Ratio | 1.95 | Debt to equity | 0.01 |
| 52w Index | 86.5 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 30.9 |
📊 JBCHEPHARM shows strong momentum for intraday trading today. RSI at 62.6 indicates bullish strength but nearing overbought territory. MACD is positive (12.4), supporting upward bias. Current price (2,101 ₹) is above both 50 DMA (2,011 ₹) and 200 DMA (1,877 ₹), reflecting short-term and medium-term strength. Volume is significantly higher than weekly average, confirming strong participation.
💡 Optimal Buy Price: Around 2,090–2,105 ₹ (support zone)
🎯 Potential Exit Levels: Profit-taking at 2,130–2,150 ₹; Stop-loss near 2,070 ₹
⏱️ If already holding intraday, consider exiting if price fails to sustain above 2,100 ₹ or if RSI crosses above 65, signaling short-term overbought conditions. Watch for resistance near 2,150 ₹ — a breakout could extend gains, but failure may trigger quick reversals.
✅ Positive
- Strong ROCE (25.9%) and ROE (20.2%)
- Stock trading above both 50 DMA and 200 DMA
- EPS at 46.5 ₹, showing solid earnings base
- FII holding increased by 1.45%
⚠️ Limitation
- High P/E ratio (46.4) compared to industry average
- PEG ratio at 1.95, suggesting expensive growth valuation
- Quarterly PAT declined slightly (179 Cr. vs 200 Cr.)
📉 Company Negative News
- DII holding decreased by -1.97%
- Sequential profit decline
📈 Company Positive News
- Quarterly profit variation up 14.6%
- Dividend yield at 0.74%
- Strong institutional support from FII inflows
🏭 Industry
- Industry PE at 30.9 vs JBCHEPHARM’s PE of 46.4 (stock overvalued compared to peers)
- Pharmaceutical sector remains resilient with strong demand outlook
🔎 Conclusion
JBCHEPHARM is a good candidate for intraday trading today, supported by bullish momentum, strong volume, and price above key moving averages. Traders can aim for gains near resistance levels, but should remain cautious of high valuation and potential profit-taking pressure. Quick exits are recommended to secure profits.